Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe
Company to Host Conference Call and Webcast Today, January 17, 2017 at 8:30 A.M. ET LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today provided further details on the development plan in the U.S. and Europe for CTP-656, a next generation CFTR potentiator being
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today announced the initiation of a U.S. -based Phase 2 clinical trial evaluating CTP-656 (deuterated ivacaftor), a next generation CFTR potentiator being developed for the treatment of cystic fibrosis.
View HTML
Toggle Summary Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results
CTP-543 to Advance into Phase 2 in First Quarter of 2017 LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today announced the Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers has been completed.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today reported financial results for the third quarter of 2016. "As we approach the end of the year, our team continues to make progress in advancing the drug
View HTML
Toggle Summary Concert Pharmaceuticals to Report Third Quarter 2016 Financial Results on November 8, 2016, and Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today announced that it will report its third quarter 2016 financial results on Tuesday, November 8, 2016 , before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Presents Poster at 2016 North American Cystic Fibrosis Conference
Clinical Results Demonstrated CTP-656's Features as Potential Next Generation, Once-Daily CFTR Potentiator for Treatment of Cystic Fibrosis LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today presented a poster describing Phase 1 food effect and multiple
View HTML
Toggle Summary Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016 , in Orlando, Florida .
View HTML
Toggle Summary Concert Pharmaceuticals Expands Management Team
Appointment of Two Executives to Support Advancement of Product Pipeline: Christine Boisclair Named Vice President, Regulatory Affairs, and Scott Weintraub Named Vice President, Commercial and Product Strategy LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals to Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2016 Healthcare Conference on September 8, 2016 at 2:20 p.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today reported financial results for the second quarter of 2016. "Concert has made significant progress with our pipeline of multiple products, including CTP-656 and
View HTML